Arbutus Biopharma announced it has reacquired the Greater China rights to its lead compound, imdusiran, from Qilu Pharmaceutical, effectively concluding their strategic partnership. This agreement means Arbutus now holds global rights for the development, manufacturing, and commercialization of imdusiran.
The reacquisition follows a mutual agreement with Qilu Pharmaceutical, driven by Qilu’s pipeline reprioritization and Arbutus’s renewed focus on advancing its pipeline efficiently. This move provides Arbutus full control over imdusiran's future development and commercial strategy worldwide.
Concurrently, Arbutus launched a new Scientific Advisory Board (SAB) composed of five globally recognized leaders in chronic hepatitis B (cHBV) treatment, including Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski, and Man-Fung Yuen. The SAB will advise on the strategic evaluation of the cHBV pipeline, aiming to leverage extensive experience in late-stage clinical trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.